Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Luke Coyle, Nicholas Morley, Alessandro Rambaldi, Kylie D. Mason, Gregor Verhoef, Caroline L. Furness, Alicia Zhang, A. Scott Jung, David Cohan, Janet Franklin
Abstract
NCT02910063.
Topics & Concepts
BlinatumomabSalvage therapyMedicineRefractory (planetary science)Internal medicineAdverse effectLymphomaCytokine release syndromeOncologyChemotherapyNon-Hodgkin's lymphomaGastroenterologyImmunotherapyCancerChimeric antigen receptorCD19AstrobiologyPhysicsPeripheral bloodCAR-T cell therapy researchLymphoma Diagnosis and TreatmentCNS Lymphoma Diagnosis and Treatment